Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
BSX heads into its October 21 earnings report with the same insider-versus-analyst tension flagged last week, but two new data points have sharpened the picture: Truist cut its target this morning and index rebalance mechanics are now pointing toward meaningful passive buying pressure tied to the Penumbra acquisition.
The most significant development since last week's note is the addition of an index flow angle. ORTEX forecasts an 80% probability that BSX receives a share-count increase in the S&P 500, tied to its agreed takeover of Penumbra. If confirmed, ORTEX estimates roughly $380 million of passive buying would be required around November 27 to 28, assuming the announcement falls around November 20. Those dates are estimated, not confirmed by the index provider. A separate CRSP US Mid share increase carries a 75% probability around December's quarterly review, implying another $610 million in forecast passive inflows. Neither is an announcement. What is notable is the potential scale: combined, the two largest flows represent close to $1 billion of mechanically driven buying if both events proceed.
The analyst community moved in the opposite direction again. Truist Securities lowered its target from $57 to $51 this morning while keeping a Buy rating, extending a pattern of declining targets that has now run for six weeks. Barclays initiated at Equal-Weight with a $48 target last week. Citigroup, Wells Fargo and Oppenheimer have all trimmed since late September. The mean target across the Street is $59.34, which represents roughly 37% above the current price of $43.31. That gap has been widening partly because targets are falling and partly because the stock is down sharply from its January highs. Bulls point to the AFib market expanding from $9 billion toward $15 billion by 2028 and the company's electrophysiology pipeline. Bears cite market share losses in radiofrequency and cryoablation procedures, slower product uptake and heightened debt levels. EPS momentum ranks in the bottom quartile of the universe on both the 30-day and 90-day windows, and forward earnings estimates are tracking below the prior year, which limits the valuation case for the near term.
Positioning is not an aggravating factor. Short interest edged up about 5% on the week to roughly 2.98% of the free float, still a low absolute level that does not add meaningful squeeze risk. Cost to borrow ticked up 72% on the week but remains at just 0.43%, well within the range of a normal, easy-to-borrow name. Availability is essentially unconstrained. Options are similarly quiet: the put/call ratio of 0.43 is almost exactly in line with its 20-day average, and the z-score of 0.09 signals no meaningful shift in hedging demand ahead of the print. A PCR of 0.43 against a 52-week high of 1.10 shows this is nowhere near a defensively positioned tape.
The insider buying documented last week remains unchanged and on the table. CEO Michael Mahoney's $9 million open-market purchase on August 3 at roughly $48.33, the CFO's nearly 10,000 shares the same week, and director David Habiger's three tranches across August 3 to 5 are all discretionary, all underwater at today's $43.31 price, and none were made under 10b5-1 plans. The stock has fallen further since last week's note. The cluster of C-suite buying is not new information but it is not getting any less relevant as the stock drifts lower into the print.
With earnings seven days away, the next focal point is how management frames market share trends in radiofrequency and cryoablation against the AFib opportunity, and whether any guidance commentary changes the trajectory of analyst targets that have been moving in one direction since August.
See the live data behind this article on ORTEX.
Open BSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
